Gapping down
In reaction to disappointing earnings/guidance: BSFT -18.5%, OWW -16.5%, PPO -13.4%, GST -10.3%, LF -10% (also downgraded to Neutral at Monness Crespi & Hardt), USU -8.5%, (light volume), MR -8.4%, MDR -8.4%, BPI -8%, (LI BDE -7.5%, (also downgraded to Neutral at DA Davidson), ANAD -7.4%, CRZO -4.7%, (announces public offering of 3.75 mln shares of common stock), THO -4.3%, HK -3.3%, ELNK -3.3%, (light volume), HW -2.9% (light volume), CF -2.1%, (light volume), APC -1.9%, (following late sell-off), GIMO -1.6%, (light volume), THC -1.6%, (light volume), IMMU -0.9%, MPEL -0.7%.
Select financial related names showing weakness: RBS -2.9%, BCS -2.9%, RBS -2.9% (downgraded to Underperform from Neutral at Exane BNP Paribas), CS -2.4%, IRE -2.4%, DB -2.3%, LYG -2.2%, SAN -2.1%, ING -1.5%, HBC -1.1%.
Select metals/mining stocks trading lower: GFI -2.9%, AU -1.4%, NEM -1.2%, CLF -1%.
Other news: IMGN -9.4% (Immunogen announces discontinuation of IMGN901 study in small-cell lung cancer; initiates Phase I testing of its EGFR-targeting ADC, IMGN289), ORAN -4.4% (still checking), EXLS -4% (discloses it received a notice of termination from The Travelers Indemnity Company; Travelers represented 9.6% of co's revs Q3 revs), FAST -3.6% (still checking), SID -3.4% (still checking), CSTM -2.7% (announces proposed secondary offering of 17.5 mln Class A ordinary shares by selling shareholders), ITMN -2.3% (announces offering of 6.5 mln shares of its common stock), EPD -2.3% ( announces commencement of a public offering of 7.5 mln common units representing limited partner interests in the partnership), PSB -2.3% (announces public offering of 1.3 mln shares of common stock), PSB -2.3% (prices public offering of 1.3 mln shares at $79.25 per share), RYAAY -1.9% (continued weakness), VNTV -1.5% (announces funds managed by Advent International have agreed to sell 15 mln shares of Vantiv's Class A common stock in secondary public offering), JCP -1.3% (still checking), EXR -1% (announces offering of 4.5 mln shares of common stock), RPRX -0.8% (receives FDA guidance for Proellex low dose oral uterine fibroid clinical program: FDA instructed co to submit a request for lifiting of the full clinical hold at the same time it submits a new protocol ).
Analyst comments: SI -1.8% (downgraded to Neutral from Buy at UBS), PSO -1.1% (downgraded to Neutral from Buy at Goldman), LINE -0.1% (downgraded to Neutral from Buy at Goldman)